Capital Research Global Investors Purchases New Shares in Sanofi $SNY

Capital Research Global Investors acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,650,018 shares of the company’s stock, valued at approximately $79,960,000. Capital Research Global Investors owned 0.07% of Sanofi at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Mondrian Investment Partners LTD bought a new stake in shares of Sanofi during the 3rd quarter valued at about $171,742,000. Raymond James Financial Inc. raised its stake in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Sanofi by 422.1% in the third quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock worth $50,165,000 after buying an additional 859,246 shares during the period. Victory Capital Management Inc. lifted its holdings in Sanofi by 133.3% in the third quarter. Victory Capital Management Inc. now owns 1,413,640 shares of the company’s stock worth $66,681,000 after buying an additional 807,767 shares during the period. Finally, Newport Trust Company LLC bought a new stake in Sanofi during the 4th quarter valued at approximately $37,421,000. 14.03% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of SNY opened at $43.88 on Tuesday. Sanofi has a fifty-two week low of $42.28 and a fifty-two week high of $52.68. The firm’s 50-day simple moving average is $45.40 and its two-hundred day simple moving average is $46.67. The stock has a market cap of $106.38 billion, a PE ratio of 12.26, a price-to-earnings-growth ratio of 1.11 and a beta of 0.34. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were given a dividend of $2.4225 per share. This is a boost from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. This represents a yield of 559.0%. Sanofi’s dividend payout ratio is 49.16%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SNY. Wall Street Zen downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Morgan Stanley set a $52.00 target price on Sanofi in a research note on Friday, May 1st. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Monday, April 20th. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Finally, Argus raised Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.